The proposed project aims to develop a dual therapeutic approach to combat viral infections (with a focus on SARS-CoV-2) by preventing viral entry and dissemination. Firstly, by inhibiting trans-infection (mediated by DC SIGN) and secondly, by inhibiting initial viral attachment via heparan sulphate (HS) and related negatively charged epitopes on host cells. This can be achieved by presenting DC-SIGN ligands and HS subunits (or glycomimetics/analogues thereof) multivalently on a biodegradable scaffold to inhibit viral attachment and dissemination with high specificity and efficiency.